Morgan Haller, CPA, CFA

Forbion

Morgan Haller is a Principal at Forbion where he focuses on supporting clinical stage therapeutics companies via Forbion's Growth Opportunities Fund. He is focused on the building and management of the portfolio across a variety of modalities and therapeutic areas.  

Previously, Morgan was a Director of the Life Sciences Investment Banking Team at Van Lanschot Kempen where he advised healthcare companies on various financing and business development transactions. Before Kempen, he was an equity research analyst covering publicly traded therapeutics companies at Point72, JP Morgan Chase, and Robert W. Baird. 

Morgan holds an MS in Accounting from the University of Virginia and a BS in Accounting from Lehigh University.